Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
India introduced a major oncology breakthrough with the launch of subcutaneous lung cancer immunotherapy. Roche Pharma India recently received CDSCO approval for Tecentriq (atezolizumab) in this new format. Consequently, this innovation promises to transform treatment for metastatic non-small cell lung cancer (NSCLC) patients across the country.
Clinicians administer the new subcutaneous therapy in approximately seven minutes. In contrast, traditional intravenous infusions usually require several hours of hospital time. Therefore, medical teams can significantly optimize their resources. Specifically, hospital chairs can now accommodate up to five patients in the time previously needed for one. However, experts expect the market price to be slightly higher than the existing IV formulation.
Clinical data from global studies confirms that the formulation maintains comparable safety and efficacy to IV delivery. Moreover, healthcare professionals report that the new method simplifies the administration process. Importantly, four out of five patients preferred the subcutaneous route. Patients cited shorter clinic visits and reduced emotional stress as primary reasons for their choice. Additionally, this shift supports the growth of decentralized cancer care in daycare centers.
Q1: How does the new delivery method affect treatment time?
It reduces the administration time from several hours for IV infusion to approximately seven minutes for a subcutaneous injection.
Q2: Has the CDSCO approved this treatment for use in India?
Yes, the CDSCO approved the subcutaneous formulation for eligible adults with adjuvant and metastatic non-small cell lung cancer.
Q3: Is the efficacy of the subcutaneous version different from the IV version?
No, clinical trials such as IMscin001 have demonstrated comparable safety and efficacy profiles between the two formulations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
India launches Roche's Tecentriq SC, a 7-minute subcutaneous lung cancer immunotherapy that reduces administration time by 80% and enhances patient comfort....
4 weeks back
A systematic review highlights influenza as a rare but life-threatening trigger for hemophagocytic lymphohistiocytosis (HLH). Learn about the clinical markers, treatment strategies involving antiviral and HLH-directed therapy, and survival rates in this comprehensive analysis.
Today
The latest National Family Health Survey (NFHS-6) outlines significant advancements in India's public health landscape, showing remarkable progress in reducing childhood stunting and boosting immunizations. However, modest gains in wasting and a concerning rise in female obesity highlight persistent challenges.
Today
The prospective VAACS study reveals that hypertension significantly alters the predictors of postoperative hallucinations after cardiac surgery. While EuroSCORE II and valve surgery predict issues in hypertensive patients, anesthesia duration is the key factor for non-hypertensive cohorts.
Today
A 2026 systematic review evaluates 29 tools for fear of movement assessment. While the Tampa Scale and others show high reliability, the review highlights critical gaps in measuring responsiveness. These findings help clinicians select the most effective tools for managing musculoskeletal pain and rehabilitation.
Today
This research explores how 3D genome architecture and epigenetic regulation control lineage identity in advanced prostate cancer, offering new insights into treatment resistance and potential therapeutic targets for castration-resistant and neuroendocrine phenotypes.
Today